Literature DB >> 30612438

Short Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy.

Ryan J Sangiovanni1,2, Bernadette Jakeman3, Mona Nasiri4, Lindsey Ruth3, Sheran Mahatme5, Nimish Patel2,6.   

Abstract

Persons living with HIV (PLWH) are at an increased risk of contraindicated drug-drug interactions (XDDIs), which may result in deleterious outcomes. Study objectives were to (1) compare the frequency of hospitalizations between patients with and without XDDIs and (2) determine if XDDIs are independently associated with hospitalizations in PLWH. A retrospective cohort study was performed among PLWH receiving care at the Upstate New York Veterans' Healthcare Administration or University of New Mexico Truman Health Services from 2000 to 2013. Hospitalization was defined as an admission to an inpatient hospital facility for ≥24 h. Of the 1329 patients evaluated, 149 (11.2%) patients were hospitalized within 1 year of antiretroviral therapy initiation. A significantly higher proportion of patients with XDDIs were hospitalized compared with those who did not have XDDIs (20.3% vs. 10.2%, risk ratio: 1.98, 95% confidence interval [CI]: 1.35-2.91, p = .001). In the multivariate Cox proportional hazards regression analyses, XDDIs were independently associated with hospitalizations (hazard ratio [HR]: 1.58; 95% CI: 1.00-2.48; p = .05), after adjustment for CD4 < 242 cells/mm3 (HR: 2.38; 95% CI: 1.72-3.33; p < .001), protease inhibitor (PI)-based regimen (HR: 1.35; 95% CI: 0.97-1.89; p = .08), recreational drug use (HR: 2.58, 95% CI: 1.85-3.58, p < .001), and non-HIV medications ≥10 (HR: 1.62; 95% CI: 0.97-2.69; p = .07). In this study an increased risk of hospitalization was observed among PLWH with XDDIs compared with those without XDDIs. This relationship persisted after adjustment for CD4 count, use of a PI-based regimen, recreational drug use, and number of non-HIV medications.

Entities:  

Keywords:  HIV; antiretroviral therapy; drug interactions; hospitalization; polypharmacy

Mesh:

Substances:

Year:  2019        PMID: 30612438      PMCID: PMC6508060          DOI: 10.1089/AID.2018.0205

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients.

Authors:  Alice Tseng; Leah Szadkowski; Sharon Walmsley; Irving Salit; Janet Raboud
Journal:  Ann Pharmacother       Date:  2013-11       Impact factor: 3.154

2.  Drug-drug interactions among elderly patients hospitalized for drug toxicity.

Authors:  David N Juurlink; Muhammad Mamdani; Alexander Kopp; Andreas Laupacis; Donald A Redelmeier
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

3.  Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.

Authors:  Bernadette Jakeman; Mona Nasiri; Lindsey Ruth; Caroline Morse; Sheran Mahatme; Nimish Patel
Journal:  Ann Pharmacother       Date:  2016-12-20       Impact factor: 3.154

4.  Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.

Authors:  Nimish Patel; Sandra Abdelsayed; Michael Veve; Christopher D Miller
Journal:  Ann Pharmacother       Date:  2011-03-08       Impact factor: 3.154

5.  Hospitalization rates of people living with HIV in the United States, 2009.

Authors:  Marcus A Bachhuber; William N Southern
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

6.  Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.

Authors:  Carol Holtzman; Carl Armon; Ellen Tedaldi; Joan S Chmiel; Kate Buchacz; Kathleen Wood; John T Brooks
Journal:  J Gen Intern Med       Date:  2013-04-20       Impact factor: 5.128

7.  Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

Authors:  Viktor von Wyl; Sabine Yerly; Jürg Böni; Philippe Bürgisser; Thomas Klimkait; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Hansjakob Furrer; Bernard Hirschel; Pietro L Vernazza; Martin Rickenbach; Bruno Ledergerber; Huldrych F Günthard
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

8.  Ageing with HIV: medication use and risk for potential drug-drug interactions.

Authors:  Catia Marzolini; David Back; Rainer Weber; Hansjakob Furrer; Matthias Cavassini; Alexandra Calmy; Pietro Vernazza; Enos Bernasconi; Saye Khoo; Manuel Battegay; Luigia Elzi
Journal:  J Antimicrob Chemother       Date:  2011-06-16       Impact factor: 5.790

9.  Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.

Authors:  Jason F Okulicz; Greg A Grandits; Jacqueline A French; Jomy M George; David M Simpson; Gretchen L Birbeck; Anuradha Ganesan; Amy C Weintrob; Nancy Crum-Cianflone; Tahaniyat Lalani; Michael L Landrum
Journal:  AIDS Res Ther       Date:  2011-05-16       Impact factor: 2.250

  9 in total
  3 in total

1.  High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction.

Authors:  Jason M Cota; Taylor M Benavides; John D Fields; Nathan Jansen; Anuradha Ganesan; Rhonda E Colombo; Jason M Blaylock; Ryan C Maves; Brian K Agan; Jason F Okulicz
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

2.  Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients.

Authors:  Jason J Schafer; Neha S Pandit; Agnes Cha; Emily Huesgen; Melissa Badowski; Elizabeth M Sherman; Jennifer Cocohoba; Ayako Shimada; Scott W Keith
Journal:  Open Forum Infect Dis       Date:  2020-12-18       Impact factor: 3.835

3.  Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study.

Authors:  Amy C Justice; Kirsha S Gordon; Jonathon Romero; E Jennifer Edelman; Benjamin J Garcia; Piet Jones; Saye Khoo; Vincent Lo Re; Christopher T Rentsch; Janet P Tate; Alice Tseng; Julie Womack; Daniel Jacobson
Journal:  Lancet Healthy Longev       Date:  2021-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.